Eli Lilly announced clinical trial results Wednesday showing its experimental weight loss medication retatrutide delivered more than twice the weight reduction of Ozempic at maximum dosage, raising questions about healthcare costs and FDA oversight as pharmaceutical companies race to dominate the booming weight loss drug market.

Clinical Trial Results Show Dramatic Differences

The phase 3 clinical trial tracked over 1,000 adults with type 2 diabetes across 80 weeks. Participants taking retatrutide’s 9mg dose lost an average of 44.3 pounds, while the 12mg dose produced 47.4 pounds of weight loss. By comparison, patients on Ozempic’s highest 2mg dose lost just 20.9 pounds during the same timeframe.

Beyond weight reduction, retatrutide demonstrated superior cardiovascular benefits, improving cholesterol levels and blood pressure markers. The medication reduced A1C levels, a critical diabetes indicator, by 2.2 percent compared to Ozempic’s 1.8 percent reduction. These combined effects could reshape treatment protocols for millions of Americans struggling with obesity and diabetes.

ABC News

@ABC

Eli Lilly’s next generation weight loss drug, known as retatrutide, was shown to provide more than double the weight loss of Ozempic’s highest dose, according to new clinical trial results shared Wednesday.

Read more: abcnews.link/hx1L3M0

11:34 AM · Oct 28, 2026

How The New Drug Works Differently

Retatrutide operates through a unique mechanism, mimicking three separate hunger-regulating hormones rather than the one or two targeted by existing medications. The once-weekly injection replicates GLP-1, GIP, and glucagon hormones. Current market leaders like Ozempic and Wegovy from Novo Nordisk only mimic GLP-1 effects, while Eli Lilly’s own Mounjaro and Zepbound combine GLP-1 and GIP.

The third hormone glucagon promotes fat burning even during rest, potentially explaining retatrutide’s enhanced effectiveness. This represents a significant pharmaceutical advancement, though the long-term safety profile remains under evaluation. Eli Lilly plans submitting retatrutide for Food and Drug Administration approval in early 2027.

Market Competition and Safety Warnings

Novo Nordisk has positioned its experimental medication CagriSema for FDA approval by year’s end, intensifying competition in this rapidly expanding market sector. Neither retatrutide nor CagriSema currently hold FDA approval, making their legal availability impossible until regulatory clearance. The FDA explicitly warned consumers against purchasing any versions appearing online, identifying such products as dangerous black market counterfeits.

Currently, only Ozempic and Mounjaro carry FDA approval for type 2 diabetes treatment, while Wegovy and Zepbound received authorization for obesity management. Healthcare providers emphasize that patients should consult qualified medical professionals before considering any prescription weight loss medication, ensuring appropriate evaluation of individual health conditions and potential risks.